NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing se… Read more
Market Cap & Net Worth: NeoGenomics Inc (NEO)
NeoGenomics Inc (NASDAQ:NEO) has a market capitalization of $1.07 Billion ($1.07 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7616 globally and #4014 in its home market, demonstrating a -7.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NeoGenomics Inc's stock price $8.27 by its total outstanding shares 129387801 (129.39 Million).
NeoGenomics Inc Market Cap History: 2015 to 2026
NeoGenomics Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.02 Billion to $1.07 Billion (3.33% CAGR).
Index Memberships
NeoGenomics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.04% | #209 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #846 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.36 Trillion | 0.10% | #436 of 602 |
Weight: NeoGenomics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NeoGenomics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NeoGenomics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.23x
NeoGenomics Inc's market cap is 3.23 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.02 Billion | $99.80 Million | -$2.54 Million | 10.20x | N/A |
| 2016 | $1.11 Billion | $244.08 Million | -$6.14 Million | 4.54x | N/A |
| 2017 | $1.15 Billion | $240.25 Million | -$396.00K | 4.77x | N/A |
| 2018 | $1.63 Billion | $276.74 Million | $2.64 Million | 5.90x | 618.02x |
| 2019 | $3.78 Billion | $408.83 Million | $8.01 Million | 9.26x | 472.72x |
| 2020 | $6.97 Billion | $444.45 Million | $4.17 Million | 15.67x | 1669.76x |
| 2021 | $4.41 Billion | $484.33 Million | -$8.35 Million | 9.12x | N/A |
| 2022 | $1.20 Billion | $509.73 Million | -$144.25 Million | 2.35x | N/A |
| 2023 | $2.09 Billion | $591.64 Million | -$87.97 Million | 3.54x | N/A |
| 2024 | $2.13 Billion | $660.57 Million | -$78.73 Million | 3.23x | N/A |
Competitor Companies of NEO by Market Capitalization
Companies near NeoGenomics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to NeoGenomics Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
NeoGenomics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, NeoGenomics Inc's market cap moved from $1.02 Billion to $ 1.07 Billion, with a yearly change of 3.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.07 Billion | -29.68% |
| 2025 | $1.52 Billion | -28.64% |
| 2024 | $2.13 Billion | +1.85% |
| 2023 | $2.09 Billion | +75.11% |
| 2022 | $1.20 Billion | -72.92% |
| 2021 | $4.41 Billion | -36.63% |
| 2020 | $6.97 Billion | +84.07% |
| 2019 | $3.78 Billion | +131.96% |
| 2018 | $1.63 Billion | +42.33% |
| 2017 | $1.15 Billion | +3.38% |
| 2016 | $1.11 Billion | +8.89% |
| 2015 | $1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NeoGenomics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.07 Billion USD |
| MoneyControl | $1.07 Billion USD |
| MarketWatch | $1.07 Billion USD |
| marketcap.company | $1.07 Billion USD |
| Reuters | $1.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.